The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) are delighted to announce a collaboration with the Children's Cancer Institute Australia for Medical Research (CCIA) for the development of an RNAi therapeutic for lung cancer. Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced that its United States-based associate company, Angioblast Systems Inc., was today featured at the 2009 UBS Global Life Sciences Conference underway in New York.
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful completion of enrolment of the second group of 20 patients randomised to receive an increased dose of Revascor(TM), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure.
Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) successful preclinical disc repair trial was featured at the World Congress on Osteoarthritis held in Montreal, Canada, over the weekend. More than 1,000 specialists in orthopaedics and rheumatology, as well as pain doctors and clinical scientists attended the prestigious congress conducted by the OsteoArthritis Research Society International (OARSI).
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced highly successful preclinical trial results of its adult stem cells in the treatment of degenerative intervertebral disc disease, the leading cause of low back pain.
Benitec Limited (ASX:BLT)(PINK:BNIKF) has now entered into binding agreements with China based Biomics Biotechnologies Co. Ltd. As previously announced, the companies are collaborating on a DNA directed (ddRNAi) or vector expressed RNAi for the treatment of chronic hepatitis B virus (HBV) infection.
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) is pleased to provide an interview with MD Silviu Itescu on its United States-based associate company Angioblast Systems Inc.
